November 10, 10:42 am
Villa Grass
Chiesi Group: reconfirmed as 1* in Italy for research and development
Dowjones
MILAN (MF-DJ) – For the 2nd consecutive year, the Chiesi group confirmed its place in 1st place among Italian investors in Research and Development in the pharmaceutical sector, 8th place in the ranking of the major national groups in each sector and 14th among pharmaceutical multinationals throughout Europe.
This is explained by the 2010 Scoreboard of European Industrial Investments in Research & Development, elaborated by the Joint Research Center (jrc) of the European Commission. The report, reads a note, was drawn up on the basis of the financial statements sent by the companies to the jrc and therefore does not represent all of the existing ones.
Thanks to the investments made in 2009, equal to 132.6 million euros (+22.1% y/y), the Parma-based group follows some of the major national companies in the ranking, such as Finmeccanica, Fiat, Telecom I. and Intesa Sanpaolo, while in the pharmaceutical sector it ranks behind large groups such as Sanofi-Aventis, GlaxoSmithKline, Astrazeneca and Boehringer Ingelheim in Europe.
In 2009, investments by the Chiesi group reached 15.2% of turnover and are in contrast with the average figure for investments made by European companies (-2.6%). com/ofb
(END) Dow Jones Newswires
November 08, 2010 11:59 AM ET (4:59 PM GMT)
Paolo Chiesi, Vice President and Director of Research and Development
Chiesi pharmaceuticals: 2009 turnover double-digit growth
